Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2037
Abstract: Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with… read more here.
Keywords: egfr mutated; mutated non; non small; cancer ... See more keywords
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-022-02128-6
Abstract: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). Serial plasma samples were collected from… read more here.
Keywords: egfr driven; patients egfr; egfr mutated; concentration egfr ... See more keywords
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.021
Abstract: INTRODUCTION Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression-free survival (PFS) than EGFR-TKI alone as first-line setting for patients with EGFR-mutant non-small-cell lung cancer (NSCLC).… read more here.
Keywords: egfr mutant; egfr tkis; tkis plus; patients egfr ... See more keywords
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2132116
Abstract: Abstract Background Osimertinib is a recently approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. The aim of the present meta-analysis was to investigate the… read more here.
Keywords: meta analysis; osimertinib; safety osimertinib; patients egfr ... See more keywords
Prediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz413.047
Abstract: Abstract Background Resistance on the 1st or 2nd generation TKIs in patients with EGFR mutated NSCLC to the therapy occurs on average after 8-12 months. The most common (49-60%) resistance mechanism is the appearance of… read more here.
Keywords: pfs; ctdna; osimertinib therapy; therapy ... See more keywords
SAT0375 Impact of febuxostat on renal function among gout patients with different renal function
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6882
Abstract: Background Febuxostat is a new xanthine oxidase inhibitor which is effective in the treatment of hyperuricemia. Its use in people with different levels of renal function has not been thoroughly assessed. Objectives To assess the… read more here.
Keywords: min patients; egfr min; function; renal function ... See more keywords
Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-049
Abstract: PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC. read more here.
Keywords: egfr alk; durvalumab may; alk nsclc; may effective ... See more keywords
Is eGFR ≥60 mL/min/1.73 m2 in Patients Undergoing Coronary Angiography Really Safe for Contrast Nephropathy?
Sign Up to like & getrecommendations! Published in 2023 at "Angiology"
DOI: 10.1177/00033197231174497
Abstract: The aim of the present study was to define the risk factors associated with contrast-induced acute kidney injury (CI-AKI) in patients who underwent coronary artery angiography (CAG). In this retrospective cohort study, patients who underwent… read more here.
Keywords: angiography; contrast; patients egfr; egfr ... See more keywords
Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Preventive Cardiology"
DOI: 10.1177/2047487317693950
Abstract: Aims The high risk of recurrent events in patients with reduced renal function following an acute coronary syndrome (ACS) may in part be due to suboptimal secondary prevention. We aimed to describe the association between… read more here.
Keywords: acute coronary; coronary syndrome; renal function; reduced renal ... See more keywords
Pulse-continuous dose erlotinib as initial targeted therapy for patients with EGFR-mutant lung cancers with untreated brain metastases.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9039
Abstract: 9039Background: Clarke (Neurooncol 2010) reported responses with intermittent high pulse doses of erlotinib (leading to higher concentrations in CSF) given to patients with EGFR-mutant central nerv... read more here.
Keywords: egfr mutant; pulse continuous; continuous dose; dose erlotinib ... See more keywords
Impact of early progression on prognosis for non-small cell lung cancer patients with EGFR mutation.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20570
Abstract: e20570Background: For epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients, EGFR-tyrosine kinase inhibitors (TKIs) improve progression free survival compared w... read more here.
Keywords: non small; cell lung; lung cancer; small cell ... See more keywords